Randomized phase III trial demonstrates improved overall survival with gemtuzumab ozogamicin in older acute myeloid leukemia patients, indicating a viable option for chemotherapy-ineligible...
First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable.
No takes yet. Share an insight, caveat, or question.
Amadori et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: